Cohance Lifesciences COHANCE
CDMO formed from Suven Pharmaceuticals and Cohance (Advent-backed), with NJ Bio adding antibody-drug-conjugate (ADC) services
Mapped in 1 theme: Pharmaceuticals.
Where Cohance Lifesciences sits in the supply chain
Cohance Lifesciences appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › CDMO & contract research
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,051 | 2,608 | 2,269 |
| Net profit | 300 | 484 | 150 |
Latest-year revenue ₹2,269 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Combined CDMO + specialty chemicals platform with ADC capability
Risks
- USFDA warning letter at its Nacharam formulation site (Feb 2026)
- FY26 profit fell to ₹150 Cr; the stock has fallen sharply in the year to Oct 2026
- Integration of several acquisitions
Common questions
What does Cohance Lifesciences do?
CDMO formed from Suven Pharmaceuticals and Cohance (Advent-backed), with NJ Bio adding antibody-drug-conjugate (ADC) services.
Where does Cohance Lifesciences sit in the supply chain?
Cohance Lifesciences (NSE: COHANCE) is mapped in 1 supply-chain layer: CDMO & contract research (Pharmaceuticals).
Who are Cohance Lifesciences' peers?
In the CDMO & contract research layer of Pharmaceuticals: Divi's Laboratories, Syngene International, Sai Life Sciences, Anthem Biosciences, Piramal Pharma, Laurus Labs and 4 more.
What is Cohance Lifesciences' market cap and valuation?
As of 30 Oct 2026: market cap ₹16,999 Cr, P/E 158.0x, ROCE 5.8%, ROE 4.9%, dividend yield 0%.